# Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

> **NCT00377962** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 282 (actual)

## Conditions studied

- Disorder Related to Cardiac Transplantation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Mycophenolic acid (MPA)/azathioprine (AZA)
- **DRUG:** Calcineurin inhibitors (CNI)
- **DRUG:** Steroids

## Key facts

- **NCT ID:** NCT00377962
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377962, "Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00377962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*